Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumor 12Solid Tumor 6Advanced Solid Tumors 5Sarcoma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Small Cell Lung Carcinoma 2Mesothelioma 2Melanoma 2Carcinoma, Renal Cell 2Anus Neoplasms 2Advanced Solid Tumour 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Germ Cell Tumor 1Stomach Neoplasms 1Solid Tumor, Adult 1Neoplasms, Unknown Primary 1Metastatic Solid Tumors 1Mesothelioma, Malignant 1Malignant Solid Tumors 1MSI-H/dMMR Solid Tumors 1MSI-H Colorectal Cancer 1Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced and Metastatic Solid Tumors 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

pembrolizumab 4toripalimab 2tislelizumab 1spartalizumab 1sintilimab 1efineptakin alfa 1camrelizumab 1atezolizumab 1Taxes 1MK 2206 1Injections 1Cyclophosphamide 1Cetuximab 1Albumin-Bound Paclitaxel 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced or Metastatic Solid Tumors × tislelizumab × Other solid neoplasm × Clear all
NCT05699811 2023-04-28

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Chinese PLA General Hospital

Phase 1/2 Recruiting
40 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡